1/13
08:30 am
pths
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
Low
Report
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
1/5
07:37 am
pths
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice [Yahoo! Finance]
Low
Report
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice [Yahoo! Finance]
1/5
07:30 am
pths
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
Low
Report
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
12/23
05:57 pm
pths
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Low
Report
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
12/10
03:50 am
pths
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript [Seeking Alpha]
Low
Report
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript [Seeking Alpha]
12/4
07:00 am
pths
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Low
Report
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
12/2
08:00 am
pths
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/13
07:06 am
pths
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results [Yahoo! Finance]
High
Report
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results [Yahoo! Finance]
11/13
06:45 am
pths
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
High
Report
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
11/7
08:00 am
pths
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
Medium
Report
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
11/5
08:00 am
pths
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
Medium
Report
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025